Equillium granted u.s. fda fast track designation for itolizumab for the treatment of lupus nephritis

Equillium granted u.s. fda fast track designation for itolizumab for the treatment of lupus nephritis.equillium - u.s. fda has granted fast track designation for itolizumab for treatment of lupus nephritis.

EQ Ratings Summary

EQ Quant Ranking